SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: johnny weissman who wrote (741)5/6/1998 10:07:00 PM
From: Ariella  Read Replies (2) | Respond to of 1491
 
Johnny -- you're being unfair to PARS. The Trout Group put this at
the opening of their spring update on the website (Tamoxifen analog),
even though an investor should NOT value a biotech company on pre-trial
possibilities. Lotemax, Alrex, and late-stage trial HU-211
are the items that should make the valuation standard for this
stock.

--Ariella



To: johnny weissman who wrote (741)5/7/1998 12:39:00 PM
From: Zvi Steinberg  Read Replies (1) | Respond to of 1491
 
Pharmos News Release:
biz.yahoo.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News